Argent BioPharma Secures Global CannEpil® Licensing Deal to Strengthen Balance Sheet
Argent BioPharma Ltd (ASX: RGT) has entered into a binding global licensing agreement for its CannEpil® therapy with Splash Beverage Group Inc., marking a significant commercial milestone for the company. The transaction provides an upfront consideration of US$5.5 million, achieved through the extinguishment of convertible debt owed to Mercer Street Global Opportunity Fund. This move is expected to strengthen Argent’s balance sheet by eliminating a major secured liability while simplifying its capital structure. Importantly, Argent retains full ownership of CannEpil®’s existing and future intellectual property and will continue manufacturing the therapy through its EU-GMP facilities. The company will also receive a 15% royalty on future net revenues generated from global CannEpil® sales, ensuring long-term commercial participation. The agreement positions Splash Beverage Group to advance regulatory development and commercialization, while allowing Argent to focus on expanding its broader neuro-immune portfolio and supporting its strategy for future growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Argent BioPharma Secures Global CannEpil® Licensing Deal to Strengthen Balance Sheet
Argent BioPharma Ltd (ASX: RGT) has entered into a binding global licensing agreement for its CannEpil® therapy with Splash Beverage Group Inc., marking a significant commercial milestone for the company. The transaction provides an upfront consideration of US$5.5 million, achieved through the extinguishment of convertible debt owed to Mercer Street Global Opportunity Fund. This move is expected to strengthen Argent’s balance sheet by eliminating a major secured liability while simplifying its capital structure. Importantly, Argent retains full ownership of CannEpil®’s existing and future intellectual property and will continue manufacturing the therapy through its EU-GMP facilities. The company will also receive a 15% royalty on future net revenues generated from global CannEpil® sales, ensuring long-term commercial participation. The agreement positions Splash Beverage Group to advance regulatory development and commercialization, while allowing Argent to focus on expanding its broader neuro-immune portfolio and supporting its strategy for future growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au